MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tardive dyskinesia(TD)"

  • 2026 International Congress

    Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Tardive Dyskinesia

    Q. Bo, A. Li, W. Dun, X. Zhang, Z. Wang, J. Li, L. Wang, W. Li, N. Li, Y. Tan, X. Xu, J. Qu, Y. Li, G. Zhang, K. Tugrul Ustundag, A. Peyser Levin, R. Ribalov, W. Lou, R. Eshet, M. Zeygarnik (Beijing, China)

    Objective: Assess real-world effectiveness and safety of deutetrabenazine (DTBZ) in Chinese adults with tardive dyskinesia (TD). Background: TD is a movement disorder associated with prolonged…
  • 2026 International Congress

    The Long-Term Efficacy of Globus Pallidus Deep Brain Stimulation in Tardive Dystonia and Dyskinesia

    G. Je, S. Miocinovic, S. Factor, S. Radmard (Atlanta, USA)

    Objective: To determine the long-term clinical outcomes and optimal stimulation sites of globus pallidus internus deep brain stimulation (GPi DBS) in patients with medically refractory…
  • 2025 International Congress

    Physical, Mental, and Socioemotional Functional Improvement Following Valbenazine Treatment for TD: a Case Series

    R. Bera, J. Nedzesky, I. Gandayuwana, D. Winkelman, D. Vanderhoef, M. Bron, M M. Perez-Rodriguez (San Diego, USA)

    Objective: Describe clinical characteristics and changes in mental, socioemotional, and physical domains of individuals with tardive dyskinesia (TD) after valbenazine (VBZ) treatment. Background: Prior research…
  • 2025 International Congress

    Exploring the Neuroprotective Potential of Raloxifene and Fulvestrant Against Haloperidol Induced Parkinson Disease; Insights into GPR30/PI3k/Akt/Nrf2 Signaling Pathways

    S. Upadhayay, P. Kumar (BATHINDA, India)

    Objective: To investigate the neuroprotective effect of raloxifene and fulvestrant on behavioral, biochemical, neurochemical, and molecular alterations in a haloperidol-induced animal model of Tardive dyskinesia.To…
  • 2025 International Congress

    Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment

    A. Cutler, L. Bahroo, K. Aldrich, E. Liu, C. Zeng, K. Farahmand (Syracuse, USA)

    Objective: To assess a potential threshold for remission of tardive dyskinesia (TD) during treatment with once-daily valbenazine, a uniquely selective vesicular monoamine transporter 2 inhibitor.…
  • 2025 International Congress

    Real-World Effectiveness of the 4-Week Patient Deutetrabenazine-Titration Kit for Tardive Dyskinesia Across Races: START Study Post Hoc Analysis

    A. Cutler, G. Alva, M. Konings, S. Finkbeiner, K. Anderson (Lakewood Ranch, USA)

    Objective: To assess the effectiveness of a 4-week deutetrabenazine (DTBZ) titration kit in patients with tardive dyskinesia (TD), stratified by race. Background: The START study…
  • 2025 International Congress

    Valbenazine Improves the Burden and Symptoms of Tardive Dyskinesia: Topline Results from the Phase 4 KINECT-PRO Study

    E. Dunayevich, A. Parameswaran, M. Bron, E. Franey, D. Sparta, C. Zeng, S. Mathias, J. Mcevoy (San Diego, USA)

    Objective: To evaluate the effects of once-daily valbenazine (VBZ) on the impacts of tardive dyskinesia (TD) using multiple patient-reported outcomes (PROs), including the psychometrically validated…
  • 2025 International Congress

    Hemichorea and Oromandibular Stereotypies Following Immunomodulatory Therapy in Multiple Myeloma: A Case Report

    P. Coss, O. Vaou, S. Horn, L. Saadatpour (San Antonio, USA)

    Objective: To describe a unique case of hemichorea and oromandibular stereotypies as a possible side effect of immunotherapy for multiple myeloma. Background: Multiple myeloma is…
  • 2025 International Congress

    Scopolamine-induced Tardive Dyskinesia: A Case Report

    H. Deville, M. Christie (Houston, USA)

    Objective: To present a case of scopolamine-related Tardive Dyskinesia (TD) and review the documented anticholinergic-associated cases of TD and the underlying pathophysiology responsible for TD.…
  • 2025 International Congress

    Bridging the Care Gap for Individuals with Drug-Induced Movement Disorders Using Telemedicine: A Randomized Pilot Study

    E. Houston, A. Kennedy, T. Rabinowitz, G. Rose, J. Boyd (Burlington, USA)

    Objective: Our goal was to evaluate the feasibility, effectiveness, and acceptability of a remote consultation with a movement disorder neurologist to patients suspected to have…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley